Consequently, using zebrafish PDX model we demonstrate that targeting of the CD44 + populations in vivo results in significantly abrogated growth of tumour bulk supporting the efficacy of therapeutic strategies targeting TICs in glioma. This evidence concerns the gene CD44 and neoplasm.